Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, ACC, PET, MAT

PURA Sales and Production Not Impacted by Coronavirus - COVID-19


DALLAS, Feb. 28, 2020 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) today announced the Coronavirus is not impacting PURA sales or production. In light of the public market performance reportedly in reaction to Coronavirus concerns, PURA management believed it worthwhile to emphasize that the Coronavirus has had no impact on PURA.

In spite of the recent market performance reportedly in reaction to the Coronavirus, PURA yesterday announced the acquisition of a CBD Infused Pet Products operation. The seller currently provides concierge pet services through an online portal and the CBD Infused Pet Product Line will bear the name of the portal. PURA will have access to the portal and the existing customer base in conjunction with the purchase agreement. The CBD pet products market is anticipated to reach $1.16 billion in the U.S. alone by 2022. PURA management plans to release more details on the CBD Infused Pet Product launch soon.

The CBD Infused Pet Products acquisition is the first in an anticipated series of acquisitions. PURA recently launched a campaign to acquire CBD infused beverage, edible and topical operations and also announced closing on a $5 million investment to fund the acquisition campaign. The $5 million investment is structured as a debt facility whereby funds can be drawn as needed to fund acquisitions. The drawn funds would be secured by the acquired asset and the debt can be repaid in stock at $0.10 per share. A second acquisition of a CBD Infused Confections operation is underway. PURA is currently working to build a pipeline of more acquisition opportunities.

For more information on Puration, visit http://www.purationinc.com.

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley
info@aciconglomerated.com
+1-(800)-861-1350

SOURCE Puration, Inc.


These press releases may also interest you

at 00:45
This updated recall warning is to provide additional information identified by the Canadian Food Inspection Agency (CFIA) during its food safety investigation.  It was determined by the CFIA that product referred to in earlier food recall warnings...

at 00:00
Dante Labs announced today its new Black Friday - Cyber Monday offering for Whole Genome Sequencing and reports for 2020. This offering is a real step toward "personalized medicine for everyone" and allows everyone to access the most advanced genetic...

at 00:00
Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug...

24 nov 2020
After a year-long search for diverse early-stage startups, Established (the company behind Startup of the Year Summit) and .US announced that Jeenie was named the .US Veteran Startup of the Year winning $10,000 non-dilutive cash prize from Summit...

24 nov 2020
CorticoMetrics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for THINQtm, its AI-based software for use by radiologists and neurologists providing quantitative information to augment patient...

24 nov 2020
In a release issued under the same headline on Friday, November 13, by Avricore Health Inc. , the units issued figure was meant to be 6,260,000, not 6,360,000. The corrected release follows: AVRICORE HEALTH INC. (the "Company" or "Avricore")...



News published on 28 february 2020 at 10:47 and distributed by: